Texas Yale Capital Corp’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-10,000
Closed -$31K 511
2025
Q4
$31K Hold
10,000
﹤0.01% 490
2025
Q3
$26.3K Hold
10,000
﹤0.01% 479
2025
Q2
$12.3K Hold
10,000
﹤0.01% 464
2025
Q1
$11K Hold
10,000
﹤0.01% 449
2024
Q4
$9.05K Buy
+10,000
New +$8.57K ﹤0.01% 460
2024
Q3
Sell
-10,000
Closed -$9.01K 460
2024
Q2
$9.01K Hold
10,000
﹤0.01% 440
2024
Q1
$11.8K Hold
10,000
﹤0.01% 442
2023
Q4
$9.13K Hold
10,000
﹤0.01% 433
2023
Q3
$8.33K Hold
10,000
﹤0.01% 422
2023
Q2
$12K Hold
10,000
﹤0.01% 440
2023
Q1
$12.6K Hold
10,000
﹤0.01% 449
2022
Q4
$21.7K Buy
+10,000
New +$82.3K ﹤0.01% 448
2022
Q1
Sell
-10,000
Closed -$113K 479
2021
Q4
$113K Hold
10,000
0.01% 453
2021
Q3
$126K Hold
10,000
0.01% 442
2021
Q2
$81K Buy
+10,000
New +$86.7K ﹤0.01% 460

Other funds holding GOSS

Texas Yale Capital Corp's GOSS Position: Q1 2026 in Review

Texas Yale Capital Corp sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 10,000 shares — an estimated $31K sold.

Texas Yale Capital Corp first reported a position in GOSS in Q2 2021 and held it in 15 quarters. The position peaked at $126K in Q3 2021. 185 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Texas Yale Capital Corp reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Texas Yale Capital Corp sold 10,000 Gossamer Bio shares in Q1 2026, an estimated $31K.
  • Texas Yale Capital Corp first reported a position in Gossamer Bio in Q2 2021 and held it in 15 quarters.
  • Texas Yale Capital Corp's Gossamer Bio position peaked at $126K in Q3 2021.
  • 185 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Texas Yale Capital Corp's 13F filing for Q1 2026, filed 4 May 2026.